The purpose of this project is to elucidate the molecular and immune pathogenesis of squamous cell neoplasms of the upper aerodigestive tract, and to enable the development of approaches for molecular and immune therapy for these disorders. Human and murine squamous cell carcinoma cell line models have been developed and used to identify genes that are differentially expressed with tumor progression using molecular and immune assays. Proinflammatory cytokines, related signal transduction pathway molecules, and immediate early transcription factor genes have been shown to be overexpressed or activated with tumor progression, and are associated with aggressive growth and metastasis. The function of these candidate genes following overexpression or inhibition by transfection of tumors with dominant negative constructs has been the subject of recent investigations to identify potential targets for molecular and immune therapy.Based upon the hypothesis that the cytokines produced by these neoplasms disrupt the immune response, studies of antigen recognition and activation of protective immune responses following treatment with recombinant and virally transduced immunoregulatory cytokines have been ongoing. The first syngeneic murine model of oral carcinoma for study of immune therapy was developed in collaboration with investigators from the University of Louisville. These studies have resulted in the identification of three cytokines with anti-tumor activity. The cellular mechanisms of immunity and molecular structure of the antigens recognized will be the subject of future investigations to determine whether therapies or vaccines using these cytokines may be suitable for human clinical trials. - cytokines, squamous cell carcinoma, interleukins, transcription factors, nuclear factor kappaB - Human Subjects

Agency
National Institute of Health (NIH)
Institute
National Institute on Deafness and Other Communication Disorders (NIDCD)
Type
Intramural Research (Z01)
Project #
1Z01DC000016-06
Application #
6289632
Study Section
Special Emphasis Panel (HNSB)
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Institute on Deafness and Other Communication Disorders
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Lu, Hai; Yan, Carol; Quan, Xin Xin et al. (2014) CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer. Neoplasia 16:789-800
Lu, Hai; Yang, Xinping; Duggal, Praveen et al. (2011) TNF-? promotes c-REL/?Np63? interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 71:6867-77
Su, Liya; Xu, Guihua; Shen, Jie et al. (2010) Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis and the cell cycle. Oncol Rep 23:3-9
Pernas, Francisco G; Allen, Clint T; Winters, Mary E et al. (2009) Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15:2361-72
Wang, Frederick; Arun, Pattatheyil; Friedman, Jay et al. (2009) Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9:389-95
Arun, Pattatheyil; Brown, Matthew S; Ehsanian, Reza et al. (2009) Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 15:5974-84
King, Kathryn E; Ponnamperuma, Roshini M; Allen, Clint et al. (2008) The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res 68:5122-31
Chen, Zhong; Yan, Bin; Van Waes, Carter (2008) The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas. Biomark Med 2:409-426
Poff, Jason A; Allen, Clint T; Traughber, Bryan et al. (2008) Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology 248:485-91
Allen, Clint; Saigal, Kunal; Nottingham, Liesl et al. (2008) Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 14:4175-85

Showing the most recent 10 out of 50 publications